Investment case
Arrowhead Pharmaceuticals, Inc.
ARWR · 10 developments mapped · last assessed 2026-09-25
Market Ontology has mapped 10 macro, policy, and market developments to Arrowhead Pharmaceuticals, Inc. since 2026-08-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ARWR yet, so no modelled value is shown. The ARWR valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ARWR on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
Increased investor confidence in RNA-based therapeutics and the broader biotech funding environment. ADARx's focus on RNA-targeting therapies could draw attention to similar companies.
· Moves peer group valuation multiples, investor perception of technology risk
- Open question
Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR
Potential future revenue streams if their investigational RNAi therapeutic for atopic dermatitis (ARO-AD1) progresses through clinical trials and gains market approval, benefiting from the expanding market.
· Moves probability of success, peak sales estimates, cost of capital
What changed, by assumption
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR
- 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
- 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
- 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share
- 2026-09-24Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-25 | ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share | mixed | 3-12m | 0.30 |
| 2026-09-25 | ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq | Bullish | 1-3m | 0.30 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share | watch | 1-3m | 0.20 |
| 2026-09-25 | ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share | watch | 1-3m | 0.30 |
| 2026-09-24 | Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026 | watch | 3-12m | 0.30 |
| 2026-09-16 | Acumen Pharmaceuticals Projects Cash Runway into Early 2027 | watch | 3-12m | 0.10 |
| 2026-09-06 | Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR | watch | 1-5y | 0.40 |
| 2026-09-06 | Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics | watch | 1-5y | 0.40 |
| 2026-09-01 | Valion Bio, Inc. Follow-On — $7.7M | watch | 3-12m | 0.10 |
| 2026-08-19 | Vogenx, Inc. IPO — $12M | watch | 3-12m | 0.20 |